Amoydx

25 /Nov

Career Opportunities - The Field Application Scientist

The Field Application Scientist is responsible for system usage training at customer sites while providing PCR/NGS experimental design, data analysis, logistical, and troubleshooting support for LATAM.

25 /Nov

Career Opportunities - Business Manager (EMEA)

You are looking for opportunities to bring to use your knowledge of and experience in oncology molecular diagnostics in qPCR and Next Generation Sequencing application? You are passionate in building meaningful relationship with both internal and external

17 /Nov

AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyD

17 /Nov

AmoyDx Distributors Annual Meeting 2022

AmoyDx celebrated its regular distributors annual meeting on November 15-16 in Dusseldorf Germany.

25 /Nov Career Opportunities - The Field Application Scientist
25 /Nov Career Opportunities - Business Manager (EMEA)
17 /Nov AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)
17 /Nov AmoyDx Distributors Annual Meeting 2022

more 

19 /Aug

Investigators Present Significant Research During WCLC 2022

Several key researches supported by Amoy Diagnostics were presented at WCLC 2022. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from mor

17 /Aug

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Vienna – Aug. 7th, 2022. – A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping).

17 /Aug

Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership

The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Pharmaceuticals Campus, where participants had discussions on recent progresses in this field.

09 /Aug

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t

19 /Aug Investigators Present Significant Research During WCLC 2022
17 /Aug AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation
17 /Aug Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership
09 /Aug MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

more 

08 /Jul

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

AmoyDx is excited to join the IASLC 2022 World Conference on Lung Cancer (Booth# 307), held in person with virtual elements in Vienna, Austria from August 6 – 9, 2022.

05 /May

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

AmoyDx will be attending the American Society of Clinical Oncology 2022 annual meeting (Booth 2052), held in person and virtually in Chicago, IL from June 3-7. We look forward to seeing you in Chicago.

20 /Apr

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx^{^®} Pan Lung Cancer PCR Panel (the “

18 /Apr

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

April 18, 2022 Shanghai, China——Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasd

08 /Jul Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,
05 /May Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA
20 /Apr Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
18 /Apr AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

more 

13 /Apr

08 /Apr

15 /Mar

14 /Mar

13 /Apr Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System
08 /Apr AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China
15 /Mar China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)
14 /Mar Visit AmoyDx at AACR Annual Meeting 2022 in Louisiana, USA

more 

Better life with AmoyDx

Better life with AmoyDx

AmoyDx won the Second Prize of National Scientific and Technological Progress Award

Better life with AmoyDx

ABOUT AMOYDX

Latest News

Career Opportunities - The Field Application Scientist

Career Opportunities - Business Manager (EMEA)

AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)

AmoyDx Distributors Annual Meeting 2022

Investigators Present Significant Research During WCLC 2022

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

New Products

New Products

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

ESMO Asia

AMP

Stock Info

Better life with AmoyDx

Better life with AmoyDx

AmoyDx won the Second Prize of National Scientific and Technological Progress Award

Better life with AmoyDx

ABOUT AMOYDX

Latest News

Career Opportunities - The Field Application Scientist

Career Opportunities - Business Manager (EMEA)

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)

AmoyDx Distributors Annual Meeting 2022

Investigators Present Significant Research During WCLC 2022

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership

MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

New Products

New Products

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HANDLE Classic NGS Panel

HRD Focus Panel

BRCA Pro Panel

ESMO Asia

AMP

Stock Info

AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer